Products for Research Use Only
RegisterLogin

Talmapimod (hydrochloride)

CAT: 0804-HY-10406ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10406ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Talmapimod (SCIO-469) hydrochloride is an orally active and selective inhibitor of p38α MAPK with an IC50 of 9 nM. Talmapimod hydrochloride inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod hydrochloride inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod hydrochloride can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) [1][2][3][4].
CAS Number
2387505-88-4
Product Name Alternative
SCIO-469 (hydrochloride)
UNSPSC
12352005
Target
Apoptosis; Interleukin Related; p38 MAPK; TNF Receptor; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/talmapimod-hydrochloride.html
Solubility
10 mM in DMSO
Smiles
O=C(N(C)C)C(C1=CN(C)C2=C1C=C(C(N3[C@H](C)CN(CC4=CC=C(F)C=C4)[C@@H](C)C3)=O)C(Cl)=C2)=O.Cl
Molecular Formula
C27H31Cl2FN4O3
Molecular Weight
549.46
References & Citations
[1]Hideshima T et al. p38 MAPK inhibition enhances PS-341 (bortezomib) -induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18, 23 (54), 8766-76.|[2]Navas T, et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma. 2008 Oct;49 (10) :1963-75.|[3]Vanderkerken K et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007 May 15;67 (10) :4572-7.|[4]Medicherla S, et al. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res. 2008 Nov-Dec;28 (6A) :3827-33.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
P38α; p38β

Related Products

CatalogName
HY-10406-01Talmapimod
HY-B0500BAlverine (hydrochloride)
HY-W714513VU0469650 (hydrochloride)
HY-W708286-01α-Pyrrolidinobutiothiophenone (hydrochloride)
HY-W492795Quifenadine (hydrochloride)
HY-W012179-01Phenylpiperazine (hydrochloride)
HY-Z6449-01Phenylephrone (hydrochloride)
HY-W209279(±) Anabasine (hydrochloride)
HY-W027446-01Pyridoxal hydrochloride
HY-W011963-01Melevodopa (hydrochloride)

Alternative Products

CatalogName
GTR19204823-01Talmapimod hydrochloride
GTR19175811-01Talmapimod
464461-01Rac-Talmapimod
MBS387421-01Talmapimod (SCIO-469)
205998Talmapimod HCl
A12770-5Talmapimod (SCIO-469) 5mg
TRC-D005580-25MGN-Desmethyl Talmapimod
A12770-2Talmapimod (SCIO-469) 2mg
A12770-50Talmapimod (SCIO-469) 50mg
A12770-100Talmapimod (SCIO-469) 100mg

Popular Products